Cannabis-Involved Emergency Department Visits Among Persons Aged <25 Years Before and During the COVID-19 Pandemic — United States, 2019–2022 🔓
To understand trends in U.S. cannabis-involved emergency department (ED) visits (i.e., those for which cannabis use was documented in the chief complaint or a discharge diagnosis) among young persons aged <25 years during the COVID-19 pandemic, CDC used National Syndromic Surveillance Program data to examine changes in ED visits during 2019–2022. Mean weekly cannabis-involved ED visits among all young persons were higher during the COVID-19 pandemic in 2020, 2021, and 2022, compared with corresponding periods in 2019. Large increases in cannabis-involved ED visits throughout the COVID-19 pandemic compared with prepandemic surveillance periods in 2019 were identified among persons aged ≤10 years. Improving clinicians’ awareness of rising cannabis-involved ED visits might aid in early diagnosis of cannabis intoxication among young persons.
Prenatal delta-9-tetrahydrocannabinol exposure is associated with changes in rhesus macaque DNA methylation enriched for autism genes 🔓
The authors cite studies showing an association between maternal cannabis use and autism spectrum disorder (ASD), ADHD, and intellectual disability in the offspring. They also note that cannabis use to treat morning sickness in pregnancy has doubled over the past decade. This study exposed pregnant, non-human primates (rhesus macaques) to THC. DNA methylation was measured in 5 tissues at delivery. They found 29 genes, candidates for ASD, methylated in THC-exposed macaques greater than the controls in all 5 tissues. This increased methylation with prenatal THC exposures reflects alterations in the epigenome that could be the underlying mechanism for the association of prenatal cannabis exposure and ASD observed in humans.
Cannabis and Cannabinoids for Pain and Posttraumatic Stress Disorder in Military Personnel and Veterans
While cannabis use in the military is low, with the expansion of legalization of marijuana, particularly for medical use, the authors review the current evidence for use of cannabis products for treatment of pain and post-traumatic stress disorders (PTSD). After review of meta-analysis, the authors found no benefit for pain with the use of cannabinoids; further, studies suggested any perceived benefits by patients were attributable to placebo effect. Similarly, across multiple studies, there did not appear to be any benefit from cannabinoids for treatment of PTSD. Based on current evidence, the authors state cannabinoid for treatment of PTSD or pain in military personnel or veterans is not supported.
Management of Posttraumatic Stress Disorder and Acute Stress Disorder 2023 🔓
VA/DoD Clinical Practice Guidelines
The guideline describes the critical decision points in the Management of Posttraumatic Stress Disorder and Acute Stress Disorder and provides clear and comprehensive evidence based recommendations incorporating current information and practices for practitioners throughout the Department of Defense and Veterans Affairs Health Care systems. The guideline is intended to improve patient outcomes and local management of patients with one of these diagnoses. The updated guidelines recommend against cannabis or cannabis derivatives for the treatment of PTSD